Protective immunity against Bordetella pertussis by a recombinant DNA vaccine and the effect of coinjection with a granulocyte-macrophage colony stimulating factor gene

Microbiology and Immunology

Volumn 50, Issue 12, 2006, Pages 929-936

  Li, Qingtian ^a,b   Zhu, Yongzhang ^a,b   Chu, Jiayou ^a   Wang, Yaying ^c   Xu, Yinghua ^c   Hou, Qiming ^c   Zhang, Shumin ^c   Guo, Xiaokui ^b  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

DNA vaccine; GM CSF; Pertussis

Indexed keywords

DNA VACCINE; FILAMENTOUS HEMAGLUTININ; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS TOXIN SUBUNIT 1; PERTUSSIS VACCINE; RECOMBINANT DNA; RECOMBINANT PERTUSSIS DNA VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BORDETELLA PERTUSSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

BORDETELLA PERTUSSIS;

EID: 33845801731     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2006.tb03869.x     Document Type: Article

References (35)

1. Barouch, D.H., Santra, S., Steenbeke, T.D., Zheng, X.X., Perry, H.C., Davies, M.E., Freed, D.C., Craiu, A., Strom, T.B., Shiver, J.W., and Letvin, N.L. 1998. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 161: 1875-1882.
2. Black, W.J., and Falkow, S. 1987. Construction and characterization of Bordetella pertussis toxin mutants. Infect. Immun. 55: 2465-2470.
3. Boros, C.A., Hanlon, M., Gold, M.S., and Roberton., D.M. 2001. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines. Vaccine 19: 3537-3542.
4. Charles, I.G., Dougan, G., Pickard, D., Chatfield, S., Smith, M., Novotny, P., Morrissey, P., and Fairweather, N.F. 1989. Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis. Proc. Natl. Acad. Sci. U.S.A. 86: 3554-3558.
5. Corbel, M.J., and Xing, D.K. 2004. Toxicity and potency evaluation of pertussis vaccines. Expert Rev. Vaccines 3: 89-101.
6. Doria-Rose, N.A., and Haigwood, N.L. 2003. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 31: 207-216.
7. Emsley, P., Charles, I.G., Fairweather, N.F., and Isaacs, N.W. 1996. Structure of Bordetella pertussis virulence factor P.69 pertactin. Nature 381: 90-92.
8. He, Q., Makinen, J., Berbers, G., Mooi, F.R., Viljanen, M.K., Arvilommi, H., and Mertsola, J. 2003. Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J. Infect. Dis. 187: 1200-1205.
9. Heininger, U. 2001. Recent progress in clinical and basic pertussis research. Eur. J. Pediatr. 160: 203-213.
10. Higuchi, R., Krummel, B., and Saiki, R.K. 1988. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 16: 7351-7367.
11. Kamachi, K., Konda, T., and Arakawa, Y. 2003. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice. Vaccine 21: 4609-4615.
12. Kamath, A.T., Hanke, T., Briscoe, H., and Britton, W.J. 1999. Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. Immunology 96: 511-516.
13. Kerr, J.R., and Matthews, R.C. 2000. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur. J. Clin. Microbiol. Infect. Dis. 19: 77-88.
14. Kim, J.J., Yang, J.S., Dentchev, T., Dang, K., and Weiner, D.B. 2000. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J. Interferon Cytokine Res. 20: 487-498.
15. Kutzler, M.A., and Weiner, D.B. 2004. Developing DNA vaccines that call to dendritic cells. J. Clin. Invest. 114: 1241-1244.
16. Leachman, S.A., Tigelaar, R.E., Shlyankevich, M., Slade, M.D., Irwin, M., Chang, E., Wu, T.C., Xiao, W., Pazhani, S., Zelterman, D., and Brandsma, J.L. 2000. Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus - rabbit model. J. Virol. 74: 8700-8708.
17. Leininger, E., Roberts, M., Kenimer, J.G., Charles, I.G., Fairweather, N., Novotny, P., and Brennan, M.J. 1991. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 88: 345-349.
18. Liu, D.F., Phillips, E., Wizemann, T.M., Siegel, M.M., Tabei, K., Cowell, J.L., and Tuomanen, E. 1997. Characterization of a recombinant fragment that contains a carbohydrate recognition domain of the filamentous hemagglutinin. Infect. Immun. 65: 3465-3468.
19. Locht, C., Antoine, R., Raze, D., Mielcarek, N., Hot, D., Lemoine, Y., and Mascart, F. 2004. Bordetella pertussis from functional genomics to intranasal vaccination. Int. J. Med. Microbiol. 293: 583-588.
20. Loosmore, S.M., Zealey, G.R., Boux, H.A., Cockle, S.A., Radika, K., Fahim, R.E., Zobrist, G.J., Yacoob, R.K., Chong, P.C., and Yao, F.L. 1990. Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine. Infect. Immun. 58: 3653-3662.
21. Martin, E., Kamath, A.T., Triccas, J.A., and Britton, W.J. 2000. Protection against virulent Mycobacterium avium infection following DNA vaccination with the 35-kilodalton antigen is accompanied by induction of gamma interferon-secreting CD4(+) T cells. Infect. Immun. 68: 3090-3096.
22. Niedziela, T., Letowska, I., Lukasiewicz, J., Kaszowska, M., Czarnecka, A., Kenne, L., and Lugowski, C. 2005. Epitope of the vaccine-type Bordetella pertussis strain 186 lipooligosaccharide and antiendotoxin activity of antibodies directed against the terminal pentasaccharide-tetanus toxoid conjugate. Infect. Immun. 73: 7381-7389.
23. Ou-Yang, P., Hwang, L.H., Tao, M.H., Chiang, B.L., and Chen, D.S. 2002. Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. J. Med. Virol. 66: 320-328.
24. Pichichero, M.E., and Casey, J.R. 2005. Acellular pertussis vaccines for adolescents. Pediatr. Infect. Dis. J. 24: S117-126.
25. Prather, K., Sagar, S., Murphy, J., and Chartrain, M. 2003. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Microb. Technol. 33: 865-883.
26. Rodriguez, M.E., and van der Pol, W.L. 2003. Humoral immunity against Bordetella pertussis: antibodies or B cells? Infect. Immun. 71: 6686.
27. Sin, J.I., Sung, J.H., Suh, Y.S., Lee, A.H., Chung, J.H., and Sung, Y.C. 1997. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene. Vaccine 15: 1827-1833.
28. Smith, A.M., Guzman, C.A., and Walker, M.J. 2001. The virulence factors of Bordetella pertussis: a matter of control. FEMS Microbiol. Rev. 25: 309-333.
29. Stagg, J., Wu, J.H., Bouganim, N., and Galipeau, J. 2004. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res. 64: 8795-8799.
30. Stevenson, F.K., Ottensmeier, C.H., Johnson, P., Zhu, D., Buchan, S.L., McCann, K.J., Roddick, J.S., King, A.T., McNicholl, F., Savelyeva, N., and Rice, J. 2004. DNA vaccines to attack cancer. Proc. Natl. Acad. Sci. U.S.A. 101 (Suppl 2): 14646-14652.
31. Sun, X., Hodge, L.M., Jones, H.P., Tabor, L., and Simecka, J.W. 2002. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine 20: 1466-1474.
32. Sykes, K.F., Lewis, M.G., Squires, B., and Johnston, S.A. 2002. Evaluation of SIV library vaccines with genetic cytokines in a macaque challenge. Vaccine 20: 2382-2395.
33. Wang, J., Zganiacz, A., and Xing, Z. 2002. Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine 20: 2887-2898.
34. Yoon, H.A., Aleyas, A.G., George, J.A., Park, S.O., Han, Y.W., Lee, J.H., Cho, J.G., and Eo, S.K. 2006. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol. Immunol. 50: 83-92.
35. Zhao, P., Cao, J., Zhao, L.J., Qin, Z.L., Ke, J.S., Pan, W., Ren, H., Yu, J.G., and Qi, Z.T. 2005. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology 331: 128-135.